Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Ocrelizumab Dose Finding Study in RRMS
NCT00676715Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2008
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 2, randomised, single-blind trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Genentech. Primary endpoint: Total Number of Gadolinium-Enhancing T1 Lesions Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain. Started Jul 2008; status: completed.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00676715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676715.